Kratom In the Chart

Pain, withdrawal, and the cost of treating this as just a supplement story

Palliative care likes to imagine that the important work starts when we walk into the room. Often it starts much earlier: in the structural failures that taught a patient to look elsewhere, in the retail and regulatory gaps that made that elsewhere easy to find, and in the stories people tell themselves when pain outlasts the patience of ordinary medicine. Kratom sits at exactly that intersection.

Start with the structure

Kratom does not become clinically relevant by magic. It becomes clinically relevant because millions of people live in a health system where pain care is uneven, opioid prescribing is politically radioactive, non-opioid options often disappoint, and access to thoughtful longitudinal symptom care is thin. The access gap falls hardest where it always does—on Black, Latino, rural, and low-income patients, the populations who were already least likely to receive adequate pain treatment before the prescribing contraction made everything worse.

In a 2025 Journal of Pain study (Mun et al.), nearly half of kratom consumers met criteria for chronic pain, pain relief was the most common reason for daily use, and 69.2% reported difficulty obtaining adequate pain treatment—difficulty that affected their decision to try kratom. That is a systems report card, and it reads badly.

People reach for kratom for reasons that should sound uncomfortably familiar: pain, mood, energy, opioid withdrawal, the wish to avoid becoming "that kind of patient," the wish to still function. NIDA's current overview notes that people report using kratom for pain, withdrawal, cravings, fatigue, and mental health symptoms, while FDA continues to warn that kratom is not approved for any medical use and is not lawfully marketed as a dietary supplement or food additive.

The public is already using it as a medicine in a regulatory world that insists it is not one. That contradiction creates the perfect breeding ground for bad history-taking, bad policy, and bad faith on all sides.

When institutions cannot decide whether something is a botanical, a supplement, an opioid-adjacent drug, or a public-health nuisance, clinicians inherit the ambiguity at the bedside. Then we act surprised when the medication list does not explain the physiology in front of us. That surprise is usually our mistake.

The "supplement" frame is obsolete

If "kratom" still conjures leaf powder in a capsule, you are behind.

FDA now distinguishes between natural kratom leaf products and products built around 7-hydroxymitragynine (7-OH), a naturally minor alkaloid with substantially greater mu-opioid receptor potency than mitragynine—and even than morphine. In July 2025, FDA asked the DEA to classify 7-OH products as Schedule I, focusing enforcement on what the Commissioner called "synthetic concentrated kratom" while leaving whole-leaf products largely untouched. California and local public-health agencies have been blunter, warning that concentrated or synthetic 7-OH products are showing up in gas stations, vape shops, smoke shops, and convenience stores—and are linked to overdose, dependence, and death.

The product landscape changed. A lot of our clinical assumptions did not.

The poison-center data fit that shift. A March 2026 CDC MMWR analysis (Towers et al.) documented roughly a 1,200% increase in kratom-related exposure reports from 2015 to 2025—from 258 to a record 3,434. The surge in 2025 coincided with the proliferation of high-potency formulations. The most severe outcomes clustered around multiple-substance exposures: nearly 80% of the 233 kratom-associated deaths over the study period involved other substances, most commonly opioids, benzodiazepines, and stimulants.

Some of your patients are taking whole-leaf products. Some are taking extracts. Some are taking products whose label says "kratom" while the pharmacology drifts much closer to concentrated opioid-adjacent retail chemistry. If your history-taking does not separate those possibilities, your problem list is already underpowered.

The evidence is messy

Kratom is not a pure anecdote.

There is a randomized, placebo-controlled, double-blind study (Vicknasingam et al., 2020) showing increased pain tolerance after kratom ingestion compared to placebo in habitual users—a small study (n=26, all male, conducted in Malaysia), but a real one. There is also the Mun et al. observational data showing that recent kratom use was associated with lower current pain levels in ecological momentary assessment. Enough evidence to stop waving this away as internet folklore.

Nowhere near enough to earn a confident statement.

A 2023 review in Current Addiction Reports concluded that the clinical evidence remains limited and uncertain despite survey data, preclinical analgesic signals, and one randomized trial. A 2024 public-health review in Frontiers in Pharmacology (Henningfield et al.) made a parallel point from the regulatory side: kratom use is no longer niche, the risks and benefits are still incompletely sorted, and better federal oversight is needed.

Here is the structural version: we have built a health-policy environment in which a compound can be common enough to shape pain behavior at scale, weakly studied enough to leave clinicians guessing, variably potent enough to cause real harm, and culturally loaded enough that every conversation about it immediately slides toward ideology. That is a terrible setup for good clinical care.

Then the patient shows up

This is where palliative care enters.

A 2025 JPSM case, memorably titled "The Kratom Bomb," described a patient with pancreatic cancer after Whipple who needed astonishing opioid doses for uncontrolled postoperative pain. His outpatient opioid history looked modest on paper (135 OMEs). His PCA dilaudid use reached the equivalent of 2,800 OMEs in 24 hours. The crucial hidden factor: recreational kratom use. The paper's lesson was plain—undisclosed kratom can dramatically alter opioid tolerance in patients whose stated history does not predict the physiology you are seeing.

A 2023 Journal of Palliative Medicine case  described a patient with stage IV lung adenocarcinoma who had been using high-dose kratom for chest pain and dyspnea. He developed kratom withdrawal after admission and, because of his history of opioid use disorder and his role managing a recovery home, was reluctant to continue full agonist opioids. The team used buprenorphine-naloxone to manage both withdrawal and cancer-related symptoms. That is palliative medicine—substance use complexity, goals-of-care alignment, and symptom management braided into a single clinical encounter.

An older surgical case report fills in the other part of the picture: postoperative kratom withdrawal presenting as confusion, agitation, hallucinations, fever, tachycardia, and ICU transfer for presumed septic shock—in a patient whose initial history did not sound particularly dramatic. The kratom use only came to light after the complications had already escalated. If you do not ask, the syndrome will introduce itself later, in a much less convenient form.

Those cases are why this belongs in Rounds & Rants and not in an addiction-medicine sidebar. The structure got the patient to kratom. The bedside pays the bill.

We are taking the wrong history

When I say we are taking the wrong history, I do not mean we need a bigger checkbox. I mean we need a different frame. "Do you use any substances?" is too vague. "Any supplements?" is too trivializing. "Any opioids?" misses the point entirely. If you want to know whether kratom is clinically relevant, you need to ask like someone who understands why people use it and what forms it now comes in.

The practical questions are not glamorous.

Ask whether they use kratom in any form: tea, powder, capsules, gummies, shots, tablets, extracts. Ask what symptom they are trying to treat. Ask how often they take it, how much, whether they feel worse when they stop, and whether they know if the product is plain kratom or an "enhanced" or 7-OH product. Ask before the PCA dose is spiraling, before the delirium differential gets crowded, before everyone starts blaming the wrong medication.

And yes, this is still a structural critique. Patients are not concealing kratom because they are plotting against us. Many are concealing it because we have taught them—quite effectively—that "supplement use" is not real medicine, that pain self-management outside the chart will be judged before it is understood, and that honesty often gets repaid with suspicion. If you want better histories, build a room where people can survive telling the truth.

How you respond

This is the part that most clinicians try to skip by appealing to policy, legality, or pharmacology.

You still have a person in front of you.

I do not think the right move is to panic, moralize, or perform expertise you do not have. I think the right move is disciplined curiosity with a spine. Something like:

"Thanks for telling me. This matters for your pain plan and for how your body may respond if we change things quickly."

Or:

"I am not asking to call you out. I am asking because this may explain why the pain picture looks stranger than it should."

Or:

"Some kratom products behave very differently from others now. I need to know what you are taking before I tell you what I think is safe."

Those are small sentences. They do a lot of work.

They keep the clinical relationship from collapsing into either collusion or contempt. They let you stay open-eyed about risk without treating the patient's improvisation as proof of bad character. And they leave room for the most important truth here: people do not usually reach for a gray-market analgesic because life is going great.

Where I might be wrong

A few pressure points deserve honesty.

First, the worst outcomes often involve polysubstance use or concentrated products. The CDC data make this clear—nearly 80% of deaths involved multiple substances. The literature is much less settled on the risk profile of traditional whole-leaf kratom alone than public-health messaging sometimes suggests. That uncertainty is real. It does not rescue us from asking better questions, but it should make us careful about treating every kratom mention like a five-alarm toxicology event.

Second, the public-health response may flatten distinctions that matter. "Kratom" now covers too much pharmacologic territory to be a useful category by itself. If we want good regulation and good clinical care, we need to get more precise than the shelf label. The FDA's move to distinguish 7-OH products from whole-leaf kratom is a step in the right direction, but clinicians will need to make that distinction at the bedside long before regulatory frameworks catch up.

Third, the evidence base for analgesic efficacy in serious illness remains thin. One controlled pain-tolerance study in habitual users, strong self-report data, and a handful of case reports are enough to take the issue seriously. They are not enough to treat kratom like an established symptom-management tool. I do not think serious people should pretend otherwise.

The cost

The cost of pretending this is just a supplement story is simple.

You will miss the driver when the pain plan stops making sense. You will miss the withdrawal when the agitation shows up dressed as something else.

You will miss the structural indictment embedded in the history—the one that says a patient found more usable help in a gas station, a smoke shop, or a Reddit thread than in the ordinary pathways we keep telling ourselves are adequate.

That should bother us more than it does.

Palliative care spends a lot of time talking about seeing the whole person. We should be willing to see the whole pharmacology, the whole retail landscape, the whole failure chain that got somebody here, and the whole relational burden of asking about it without either flinching or sneering.

Kratom is already in the chart, whether we write it down early or not.

I am a palliative care physician, educator, and professional strategery expert. Known for turning rounds into rants and rants into teaching points. Rounds & Rants represents my views — not those of any institution or professional membership organization where I hold a role. I don't write on their behalf and they don't vet what I publish.